Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.51 |
| ▸ | HTR3B | O95264 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | BPTF | Q12830 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388809 | 1.00 | ADRB2 (0.97) | ADRB2HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL5585896 | 0.98 | ADRB2 (1.00) | ADRB2HTR3EHTR3BHTR3AHTR3D | |
| Tert-Butyl Formate SCHEMBL27809039 | 0.87 | ADRB2 (0.74) | ADRB2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23779626 | 0.84 | ADRB2 (0.70) | ADRB2ALDH1A1CYP1A2MAPK1HTT | |
| SCHEMBL12780912 | 0.84 | ADRB2 (0.70) | ADRB2ALDH1A1CYP1A2MAPK1HTT | |
| SCHEMBL12763838 | 0.81 | ADRB2 (0.67) | ADRB2CYP1A2LCATCXCR3 | |
| SCHEMBL5585596 | 0.80 | ADRB2 (0.65) | ADRB2ALDH1A1HTR2CLCATCXCR3 | |
| SCHEMBL5585785 | 0.80 | ADRB2 (0.65) | ADRB2ALDH1A1HTR2CLCATCXCR3 | |
| SCHEMBL5585598 | 0.80 | ADRB2 (0.65) | ADRB2ALDH1A1HTR2CLCATCXCR3 | |
| SCHEMBL25390151 | 0.80 | ADRB2 (0.65) | ADRB2CYP1A2CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014195695-A1 | THERAPEUTIC COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-12-11 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | claimed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | claimed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | claimed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | claimed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| US-20040038985-A1 | Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride | AKZO NOBEL N.V. (NL) | 2004-02-26 | — | — | US | claimed |
| EP-1326837-A1 | CRYSTAL FORMS OF 1- 6-CHLORO-5-(TRIFLUOROMETHYL)-2-PYRIDINYL]PIPERAZINE.HYDROCHLORIDE | Akzo Nobel N.V. (NL) | 2003-07-16 | — | — | EP | claimed |
| US-20030040519-A1 | Use of serotonergic compound for a method of treatment of hot flushes in post-menopausal women | AKZO NOBEL N.V. (NL) | 2003-02-27 | — | — | US | claimed |
| US-20030032646-A1 | Use of serotonergic compound for a method of treatment of hot flushes in post-menopausal women | N.V. ORGANON (NL) | 2003-02-13 | — | — | US | claimed |
| US-20020103206-A1 | Serotonergic compound for a method of treatment of hot flushes in post-menopausal women | N.V. ORGANON (NL) | 2002-08-01 | — | — | US | claimed |
| EP-1213017-A2 | Use of a 5-HT2C receptor agonist for the treatment of hot flushes | Akzo Nobel N.V. (NL) | 2002-06-12 | — | — | EP | claimed |
| WO-2002030902-A1 | CRYSTAL FORMS OF 1-[6-CHLORO-5-(TRIFLUOROMETHYL)-2-PYRIDINYL]PIPERAZINE.HYDROCHLORIDE | AKZO NOBEL N.V. (NL) | 2002-04-18 | — | — | WO | claimed |
| WO-1998033504-A1 | TREATMENT OF URINARY INCONTINENCE | AKZO NOBEL N.V. (NL) | 1998-08-06 | — | — | WO | claimed |
| EP-0370560-B1 | Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines | AKZO NV (NL) | 1994-01-12 | — | — | EP | claimed |
| US-4971969-A | NERVOUS SYSTEM DISORDERS | AKZO N.V. (NL) | 1990-11-20 | — | — | US | claimed |
| EP-0370560-A1 | Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines | Akzo Nobel N.V. (NL) | 1990-05-30 | — | — | EP | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| WO-1998033504-A1 | TREATMENT OF URINARY INCONTINENCE | AKZO NOBEL N.V. (NL) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | ADRB2 14/4885HTR3E 13/4885HTR3B 5/4885 |
| US-20040038985-A1 | Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride | HTR5A, HTR1B, SEC62 | ADRB2 624/4885HTR3E 68/4885HTR3B 10/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | ADRB2 14/4885HTR3E 13/4885HTR3B 5/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | ADRB2 14/4885HTR3E 13/4885HTR3B 5/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | ADRB2 32/4885HTR3E 12/4885HTR3B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.